Chinook Therapeutics Nabs Rare Pediatric Disease Tag For CHK-336 In Primary Hyperoxaluria

by Vandana Singh, Benzinga Editor

February 2, 2021 11:23 AM | 1 min read |

The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Inc's (NASDAQ: KDNY) CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxaluria (PH), a rare genetic disorder that mainly affects the kidneys and results from a buildup of a substance called oxalate.
Rare Pediatric Disease designation provides for the issuance of a priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or sold to a third party.
CHK-336 is currently progressing through IND-enabling studies, with a Phase 1 study planned for the second half of 2021.
Price Action: KDNY stock is up 3.52% at $15.89 on the last check Tuesday.
Related News: Travere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder Study

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.